Bowen Anthony, Casadevall Arturo
Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461;
Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461; Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205
Proc Natl Acad Sci U S A. 2015 Sep 8;112(36):11335-40. doi: 10.1073/pnas.1504955112. Epub 2015 Aug 17.
Society makes substantial investments in biomedical research, searching for ways to better human health. The product of this research is principally information published in scientific journals. Continued investment in science relies on society's confidence in the accuracy, honesty, and utility of research results. A recent focus on productivity has dominated the competitive evaluation of scientists, creating incentives to maximize publication numbers, citation counts, and publications in high-impact journals. Some studies have also suggested a decreasing quality in the published literature. The efficiency of society's investments in biomedical research, in terms of improved health outcomes, has not been studied. We show that biomedical research outcomes over the last five decades, as estimated by both life expectancy and New Molecular Entities approved by the Food and Drug Administration, have remained relatively constant despite rising resource inputs and scientific knowledge. Research investments by the National Institutes of Health over this time correlate with publication and author numbers but not with the numerical development of novel therapeutics. We consider several possibilities for the growing input-outcome disparity including the prior elimination of easier research questions, increasing specialization, overreliance on reductionism, a disproportionate emphasis on scientific outputs, and other negative pressures on the scientific enterprise. Monitoring the efficiency of research investments in producing positive societal outcomes may be a useful mechanism for weighing the efficacy of reforms to the scientific enterprise. Understanding the causes of the increasing input-outcome disparity in biomedical research may improve society's confidence in science and provide support for growing future research investments.
社会在生物医学研究方面投入了大量资金,旨在寻找改善人类健康的方法。这项研究的成果主要是发表在科学期刊上的信息。对科学的持续投资依赖于社会对研究结果的准确性、诚实性和实用性的信任。最近,对科研产出的关注主导了对科学家的竞争性评估,这促使人们最大化论文发表数量、引用次数以及在高影响力期刊上的发表量。一些研究还表明,已发表文献的质量在下降。然而,社会在生物医学研究方面的投资效率,即对改善健康结果的影响,尚未得到研究。我们发现,尽管资源投入和科学知识不断增加,但根据预期寿命和美国食品药品监督管理局批准的新分子实体数量来估算,过去五十年来生物医学研究成果一直相对稳定。在此期间,美国国立卫生研究院的研究投资与论文发表数量和作者数量相关,但与新型疗法的数量发展无关。我们考虑了投入产出差距不断扩大的几种可能性,包括较容易的研究问题已被优先解决、专业化程度提高、过度依赖还原论、对科学产出的过度强调以及对科学事业的其他负面压力。监测研究投资在产生积极社会成果方面的效率,可能是衡量科学事业改革成效的有用机制。了解生物医学研究中投入产出差距不断扩大的原因,可能会增强社会对科学的信心,并为未来增加研究投资提供支持。